In our hypothesis, Rg3 would prevent the formation and activation of CAFs by inhibiting the secretion of TGF-β from tumor cells and inhibiting the subsequent CAFs-induced physical and immune barriers in TME. The gene discussed is TGFB1; the disease is neoplasm.